Hugues Dolgos

Hugues Dolgos has extensive experience in the pharmaceutical industry, particularly in the field of oncology. Hugues is currently serving as the Chief Executive Officer of NMS Group, an R&D organization focused on discovering and developing life-saving molecules for patient health. Hugues is also the Chairperson of the Board at Accelera, a contract research organization that supports pharmaceutical and biotechnology companies in advancing their drug candidates. Additionally, Hugues holds the position of Chairperson of the Board and CEO at NerPharMa, which specializes in the development and production of medicinal agents. Hugues is also the Chairperson of the Board and CEO at Nerviano Medical Sciences, a leader in delivering innovative cancer treatments.

Furthermore, Hugues Dolgos is a Board Member at Skymab Biotherapeutics and a Scientific Advisory Board Member at CERES BRAIN Therapeutics. Prior to their current roles, they served as the Global Head of Oncology at Servier and held positions of Deputy Director Biopharmacy and Chairperson at Medicen Paris Region. In addition, Hugues has held leadership positions at Merck Group and Merck Serono, where they contributed to R&D strategy, quantitative pharmacology, drug disposition, translational medicine strategy implementation, and global DMPK.

Hugues Dolgos attended Université Paris Cité from 1988 to 1996. Hugues studied Pharmacy, Analytical Chemistry, and Pharmaceutical Sciences. No degree information is provided.